Literature DB >> 17105987

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

James J Dignam1, Blase N Polite, Greg Yothers, Peter Raich, Linda Colangelo, Michael J O'Connell, Norman Wolmark.   

Abstract

BACKGROUND: Although several studies have established a link between obesity and colon cancer risk, little is known about the effect of obesity on outcomes after diagnosis. We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials.
METHODS: The study cohort consisted of 4288 patients with Dukes B and C colon cancer who were accrued from July 1989 to February 1994 to National Surgical Adjuvant Breast and Bowel Project randomized trials. Risk of recurrence, second primary cancer, and mortality (overall and by likely cause) were evaluated in relation to BMI at diagnosis using statistical modeling. Median follow-up time was 11.2 years. All statistical tests were two-sided.
RESULTS: Very obese patients (BMI > or = 35 kg/m2) had greater risk of a colon cancer event (recurrence or secondary primary tumor; hazard ratio [HR] = 1.38, 95% confidence interval [CI] = 1.10 to 1.73) than normal weight patients (BMI = 18.5-24.9 kg/m2). Mortality was greater for very obese (HR = 1.28, 95% CI = 1.04 to 1.57) and underweight (BMI < 18.5 kg/m2) (HR = 1.49, 95% CI = 1.17 to 1.91) than for normal weight patients. The increased risk of mortality for underweight patients was dominated by non-colon cancer deaths (HR of such deaths compared with normal weight patients = 2.23, 95% CI = 1.50 to 3.31), whereas for the very obese, deaths likely due to colon cancer were increased (HR = 1.36, 95% CI = 1.06 to 1.73).
CONCLUSIONS: Among colon cancer patients, a BMI greater than 35.0 kg/m2 at diagnosis was associated with an increased risk for recurrence of and death from colon cancer. Further studies are needed to determine pathways between obesity and recurrence risk and whether weight reduction or related interventions would improve prognosis.

Entities:  

Mesh:

Year:  2006        PMID: 17105987     DOI: 10.1093/jnci/djj442

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  135 in total

Review 1.  Adipokines as novel biomarkers and regulators of the metabolic syndrome.

Authors:  Yingfeng Deng; Philipp E Scherer
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

Review 2.  Obesity in cancer survival.

Authors:  Niyati Parekh; Urmila Chandran; Elisa V Bandera
Journal:  Annu Rev Nutr       Date:  2012-04-23       Impact factor: 11.848

Review 3.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

4.  Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.

Authors:  Kenneth R Carson; Nancy L Bartlett; Jay R McDonald; Suhong Luo; Angelique Zeringue; Jingxia Liu; Qiang Fu; Su-Hsin Chang; Graham A Colditz
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 5.  Energetics in colorectal and prostate cancer.

Authors:  Jeffrey A Meyerhardt; Jing Ma; Kerry S Courneya
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

6.  Visceral Adiposity is a Risk Factor for Poor Prognosis in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy.

Authors:  Chun Seng Lee; David J Murphy; Colm McMahon; Blathnaid Nolan; Garret Cullen; Hugh Mulcahy; Kieran Sheahan; Elizabeth Barnes; David Fennelly; Elizabeth J Ryan; Glen A Doherty
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 7.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

8.  Dosing of chemotherapy in obese and cachectic patients: results of a national survey.

Authors:  Helena Anglada-Martínez; Gisela Riu-Viladoms; Fernando do Pazo-Oubiña; Gloria Molas-Ferrer; Irene Mangues-Bafalluy; Carles Codina-Jané; Natàlia Creus-Baró
Journal:  Int J Clin Pharm       Date:  2014-04-27

9.  Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008).

Authors:  Heather Greenlee; Danika L Lew; Dawn L Hershman; Vicky A Newman; Lisa Hansen; Sheri J Hartman; Judith Korner; Zaixing Shi; Christine L Sardo Molmenti; Antoine Sayegh; Lou Fehrenbacher; Shelly Lo; Jennifer Klemp; Kristine Rinn; John M Robertson; Joseph Unger; Julie Gralow; Kathy Albain; Robert Krouse; Carol Fabian
Journal:  Obesity (Silver Spring)       Date:  2018-09-11       Impact factor: 5.002

10.  Cohort study of fatty acid synthase expression and patient survival in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Jeffrey A Meyerhardt; Gregory J Kirkner; Andrew T Chan; Takako Kawasaki; Edward L Giovannucci; Massimo Loda; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.